BIZARRE: 18 | Mind Blowing Facts

Continuous glucose monitors: should people who don’t live with diabetes be wearing them?

Gwyneth Paltrow and other celebrities and influencers are sporting CGMs, but counting your glucose levels provides little benefit if you don’t have diabetes

The Guardian - AU · Aug 19, 2025

Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks

On Tuesday, Viking Therapeutics Inc. (NASDAQ:VKTX) released the much-awaited data from its Phase 2 trial of VK2735 pill, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

Benzinga · Aug 19, 2025

Ozempic price slashed following Donald Trump's demands - will it impact the UK cost?

Novo Nordisk said it has no plans to rise UK prices, despite pressure from Trump

Evening Standard · Aug 19, 2025

Millions of people ‘could be denied weight-loss jabs due to flawed NHS guidance’

NHS BMI measures ‘don’t work for around 3 million patients’, a health analyst has warned

The Independent UK · Aug 15, 2025

Mounjaro weight-loss drug price to almost triple in UK after Trump complaint

At least 500,000 people in the UK take either Mounjaro or Wegovy, another weight-loss jab, through private prescriptions

The Independent UK · Aug 14, 2025

Drug that slows onset of type 1 diabetes licensed for use in UK-first

The cost-effectiveness of the drug for NHS roll-out will now be assessed by the National Institute for Health and Care Excellence.

Evening Standard · Aug 14, 2025

Eli Lilly To Raise Mounjaro Price In UK, Expands Obesity Drug Push In India

Eli Lilly and Co. (NYSE:LLY) will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom, while expanding its market presence in India with a new injector pen.

Benzinga · Aug 14, 2025

Weighing The Costs: Obesity Drug Users Make Financial Sacrifices As Coverage Tightens

Vacations are on hold, dinners out skipped, and doses stretched — all so patients can keep taking weight-loss drugs like Wegovy and Zepbound as insurers pull back coverage in 2025.

Benzinga · Aug 13, 2025

UK Government, Eli Lilly Partner To Target Obesity Health Gaps

A new program to improve access to weight management services across the U.K. National Health Service (NHS) could benefit several obese patients.

Benzinga · Aug 12, 2025

Study links weight-loss drugs to serious eye conditions and vision loss

Researchers suggest all diabetes patients on weight-loss drugs should be regularly screened and monitored for potential eye complications

The Independent UK · Aug 12, 2025